Simple blood test may predict lung cancer recurrence

NCT ID NCT07170046

Not yet recruiting Knowledge-focused Sponsor: Guangdong Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will follow 100 lung cancer patients after surgery to see if levels of CEA and ctDNA in the blood can predict whether the cancer comes back. Participants will have regular blood tests and imaging over two years. The goal is to catch recurrence earlier and tailor follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors predict lung cancer recurrence earlier after surgery, allowing for more timely and personalized treatment adjustments.

What could go wrong

This is an observational study, not a treatment trial. It is small (100 people) and has not started recruiting yet, so results are uncertain and may not apply to all lung cancer patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung carcinoma lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CARCINOMA